ArticleJournal of immunology (Baltimore, Md. : 1950)1996
Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen.
Article in Journal of immunology (Baltimore, Md. : 1950), 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 137 citations in OpenAlex.
- Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.Journal of immunology (Baltimore, Md. : 1950) · 1999Trial
- Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.Journal of the National Cancer Institute · 1998Trial
- Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products.The Journal of clinical investigation · 1997Trial
- Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Harnessing the Microbiome to Enhance Cancer Immunotherapy.Journal of immunology research · 2015Review
- Photodynamic therapy plus regulatory T-cell depletion produces immunity against a mouse tumour that expresses a self-antigen.British journal of cancer · 2013Article
- Adoptive immunotherapy for cancer: harnessing the T cell response.Nature reviews. Immunology · 2012Review
- Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine.PloS one · 2012Article
- Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins.Frontiers in oncology · 2012Article
- Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response.PloS one · 2010Article
- Human dendritic cells infected with an adenoviral vector suppress proliferation of autologous and allogeneic T cells.Immunology · 2008Article
- Therapeutic vaccines for non-Hodgkin B-cell lymphoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2008Review
- Toll-like receptors in tumor immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2007Review
- Immunotherapy success in prophylaxis cannot predict therapy: prime-boost vaccination against the 5T4 oncofoetal antigen.Cancer immunology, immunotherapy : CII · 2007Article
- Immune characterization of clinical grade-dendritic cells generated from cancer patients and genetically modified by an ALVAC vector carrying MAGE minigenes.Cancer gene therapy · 2005Article
- Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid.The Journal of clinical investigation · 2005Article
- Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses.Journal of virology · 2004Article
- Human papillomavirus therapy for the prevention and treatment of cervical cancer.Current treatment options in oncology · 2003Review
- Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines.Gene therapy · 2003Article
- Efficacy of recombinant adenovirus as vector for allergen gene therapy in a mouse model of type I allergy.Gene therapy · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Recombinant adenovirus (rAd), deleted of critical genes that enable viral replication and replaced with genes encoding heterologous proteins, has been shown to be a safe and effective vector in gene therapy studies. To evaluate a potential role for rAd as an immunogen, we used two different replication-defective type 2 rAds encoding the model Ag, beta-galactosidase (beta-gal). To determine whether rAd elicited the kind of immune responses therapeutic in an anti-tumor setting, the beta-gal-expressing adenocarcinoma, CT26.CL25, was used. Splenocytes from BALB/c mice immunized with 1 x 10(7) infectious units (iu) of rAd demonstrated anti-beta-gal activity after in vitro culture with the relevant L(d) beta-gal peptide. Adoptive transfer of these same splenocytes produced dramatic regression of established pulmonary metastases. However, when tumor-bearing mice were treated with 1 x 10(7) iu of rAd, no reduction in established disease was observed even when rAd was given with exogenous IL-2. To increase the viral dose delivered to each animal, we used an E1-E4-deleted rAd that could be grown to much higher titers. Significant reduction occurred with 10-fold more rAd (1 x10(8) iu) was administered. Exogenous IL-2 administration with 1 x 10(8) iu of rAd resulted in augmentation of this anti-tumor effect. These findings demonstrate that when using a nonreplicating virus, the viral dose is directly related to the immune response generated. These data constitute the first reported use of rAd in the treatment of an established experimental cancer and may have implication for the treatment of human cancer.
Indexed as
Identifiers
8598466PMC1950465W1543077929What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.